Understanding the differences in progression of kidney disease caused by genetic mutations.
Official title: Differentiating slow from rapidly progressive ADPKD by cell-specific mitochondrial and transcriptional profiles
Funded at University of Alabama at Birmingham · NIH-11063242 · Data updated 2026-11-12
This study is looking at how certain changes in kidney cells might affect how quickly autosomal dominant polycystic kidney disease (ADPKD) gets worse, so that doctors can find better ways to tailor treatments for patients based on their unique disease patterns.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | April 1, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $489,684 |
| NIH project number | 5R01DK134310-02 |
| Project ID | NIH-11063242 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with autosomal dominant polycystic kidney disease, particularly those experiencing varying rates of disease progression.
✕Less likely to help
Patients with other forms of kidney disease or those without a diagnosis of ADPKD may not benefit from this research.
What this research studies
This research investigates how mitochondrial function and gene expression differ in patients with autosomal dominant polycystic kidney disease (ADPKD), which can lead to varying disease progression rates. By analyzing kidney tissues and using animal models, the study aims to identify specific biomarkers that could help differentiate between slow and rapidly progressing forms of the disease. The goal is to uncover new therapeutic targets that could improve patient outcomes and quality of life. Patients may benefit from a more personalized approach to treatment based on their specific disease characteristics.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools and targeted therapies for patients with ADPKD.
How similar studies have gone: Previous research has shown promise in understanding mitochondrial dysfunction in kidney diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Lasseigne, Brittany Nicole — University of Alabama at Birmingham
- Study coordinator: Lasseigne, Brittany Nicole
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.